Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 8042
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Exquis, B. Articles by Kohler, S. Search for Related Content PubMed Articles by Exquis, B. Articles by Kohler, S.

Abstract

Oxaliplatin (with 5FU and leucovorin ) in patients above age 70 ( «elderly» ) suffering from metastatic colorectal cancer: An observational study

Groupe Médical Onex, Onex, Switzerland; IMO Clinique de Genolier, Genolier, Switzerland; Sanofi-Synthélabo Suisse, Meyrin, Switzerland

8042

Background: Data on standard chemotherapy in the real elderly are rare. Patients and Methods: We conducted, during 18 months, an observational study of Oxaliplatin in combination with 5-FU and leucovorin (FUFOL) for treatment of metastatic colorectal cancer, in order to assess safety, response rate and exact regimens used in patients below and above 70 years. Twenty-five centres documented 137 patients (57% male, median age 62 years, colon/rectum/other: 64%/30%/6%, ECOG PS 0/1/2/3: 34%/55%/10%/1%, previous chemotherapy: 69%). Total number of administered cycles was 816 (median 6, range 1–23). Results: : 71% received Eloxatin at 85mg/m² every 2 weeks, 18% at 130mg/m² every 3 weeks, and 11% received other regimens. FUFOL regimens were 37% FOLFOX4, 27% simplified 46h infusion, 21% weekly bolus (Roswell Park), 8% daily bolus (Mayo), 7% others. : CR 4%, PR 21%, SD 37, PD 27%, unknown 11%. ECOG PS before vs. after therapy: 20% of patients improved, 62% stable, 18% deteriorated. : Grade 3/4 toxicities (per cycle) were nausea (0.1%), vomiting (0.5%), diarrhea (2%), stomatitis (0.2%), thrombocytopenia (1%), leucocytopenia (1%), granulocytopenia (0.6%), lymphocytopenia (7.2%). 75% no hair loss, 18% had mild and 7% had grade 2 hair loss. Grade 3 neuropathy (Levy scale) was reported by 3%. These 4 patients had at least tumor stabilisation or partial response. : 33 patients were older than 70. Overall response rate was 24% for patients up to 70 years and 27% for older patients. Grade 3/4 toxicities (per cycle) were (70/>70 years): nausea 0.3%/0.0%, vomiting 0.7%/0.0%, diarrhea 1.8%/2.8%, stomatitis 0.4%/0.0%, neuropathy 0.7%/0.0%. Conclusion: Combination therapy with Eloxatin as used here is safe and efficacious in daily practice. Elderly patients benefit equally from therapy without increased toxicity.

View larger version (11K): [in this window] [in a new window]

Abstract presentation from the 2004 ASCO Annual Meeting